SARS-CoV-2 RNA expression in ex vivo infection. by Corantin Maurin (9155070)

PEITC induces nuclear accumulation of p-STAT3 and regulates its target gene expression in differentiated SH-SY5Y cells. by Miho Yagi (5921252)

Comparison of variable distributions between the women in SAVOR-TIMI 53 trial based dataset v.s. the virtual patient dataset. by Yasunori Aoki (339027)

Comparison of variable distributions between the women in SAVOR-TIMI 53 trial based dataset v.s. the virtual patient dataset. by Yasunori Aoki (339027)

<i>Med23</i> deletion causes decreased H3K9me2 occupancy among the promoter of <i>Ccl5</i> and <i>Cxcl10</i>. by Zhichao Wang (3570413)

AvcID reduces the functionality of T5 but not T7 phage. by Brian Y. Hsueh (16955722)

Ts5 recognition by scorpion antivenom and predicted epitopes. by Felipe Cerni (3477902)

Purification of IgG anti-Ts5 antibodies. by Felipe Cerni (3477902)

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

ApoE, MMP-9, Claudin-5, and Occludin Protein Expression. by Lu Xu (386491)

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”